TrialEuropean journal of neurology2024

Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.

Messoud Ashina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.